AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 22.27 USD 5.2% Market Closed
Market Cap: 677.7m USD
Have any thoughts about
AnaptysBio Inc?
Write Note

AnaptysBio Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AnaptysBio Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
Revenue
$57.2m
CAGR 3-Years
-22%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
677.7m USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
18.18 USD
Overvaluation 18%
Intrinsic Value
Price

See Also

What is AnaptysBio Inc's Revenue?
Revenue
57.2m USD

Based on the financial report for Sep 30, 2024, AnaptysBio Inc's Revenue amounts to 57.2m USD.

What is AnaptysBio Inc's Revenue growth rate?
Revenue CAGR 5Y
63%

Over the last year, the Revenue growth was 282%. The average annual Revenue growth rates for AnaptysBio Inc have been -22% over the past three years , 63% over the past five years .

Back to Top